1	Toxoplasma gondii infection and insomnia: a case control
2	seroprevalence study
3	
4	Short title: Toxoplasma and insomnia.
5	
6	Cosme Alvarado-Esquivel <sup>1</sup> , Sergio Estrada-Martínez <sup>2</sup> , Alma Rosa Pérez-Álamos, <sup>2</sup> Agar
7	Ramos-Nevarez, <sup>3</sup> Karina Botello-Calderon, <sup>1</sup> Ángel Osvaldo Alvarado-Félix, <sup>1</sup> Raquel
8	Vaquera-Enríquez, <sup>4</sup> Gustavo Alexis Alvarado-Félix, <sup>1</sup> Antonio Sifuentes-Alvarez <sup>1</sup> , Carlos
9	Alberto Guido-Arreola, <sup>3</sup> Elizabeth Rábago-Sánchez <sup>1</sup> , Leandro Saenz-Soto. <sup>3</sup>
10	
11	<sup>1</sup> Biomedical Research Laboratory. Faculty of Medicine and Nutrition, Juárez University of
12	Durango State. Avenida Universidad S/N. 34000 Durango, Mexico.
13	<sup>2</sup> Institute for Scientific Research "Dr. Roberto Rivera-Damm", Juárez University of Durango
14	State. Avenida Universidad S/N. 34000 Durango, Mexico.
15	<sup>3</sup> Clínica de Medicina Familiar. Instituto de Seguridad y Servicios Sociales de los
16	Trabajadores del Estado. Predio Canoas S/N. 34079 Durango, Mexico.
17	<sup>4</sup> Health Center No. 2 "Dr. Carlos Santamaría". Servicios de Salud de Durango. Durango,
18	Mexico. Talpa S/N. 34170 Durango, Mexico.
19	
20	

21 Corresponding author:

22	Dr. Cosme Alvarado-Esquivel. Laboratorio de Investigación Biomédica. Facultad de
23	Medicina y Nutrición. Avenida Universidad S/N. 34000 Durango, Dgo, México. Tel/Fax:
24	0052-618-8271380. Email: cosmealvarado@ujed.mx
25 26 27	E-mail addresses:
28	CAE: alvaradocosme@yahoo.com
29	SEM: semdurango@hotmail.com
30	ARPA: almaross1@yahoo.es
31	ARN: agar_ramos@hotmail.com
32	KBC: kary09botellocalderon@gmail.com
33	AOAF: aoafangel@hotmail.com
34	RVE: raqueenriquez@hotmail.com
35	GAAF: gaafalexis15@gmail.com
36	ASA: sifual55@hotmail.com
37	CAGA: drguido1@hotmail.com
38	ERS: rabagopediatria@hotmail.com
39	LSS: quim_saenz@hotmail.com
40	
41	
42	
43	
44	

## 46 ABSTRACT

47 Aim: To determine the association between *Toxoplasma gondii* (*T. gondii*) infection and
48 insomnia.

49 Materials and methods: Through an age-and gender-matched case-control study, 577 50 people with insomnia (cases) and 577 people without insomnia (controls) were tested for 51 anti-*T. gondii* IgG and IgM antibodies using commercially available enzyme-immunoassays. 52 **Results:** Anti-*T. gondii* IgG antibodies were found in 71 (12.3%) of 577 individuals with 53 insomnia and in 46 (8.0%) of 577 controls (OR=1.62; 95% CI: 1.09-2.39; P=0.01). Men with 54 insomnia had a higher (16/73: 21.9%) seroprevalence of T. gondii infection than men without 55 insomnia (5/73: 6.8%) (OR: 3.81; 95% CI: 1.31-11.06; P=0.009). The rate of high (>150 56 IU/ml) anti-T. gondii IgG antibody levels in cases was higher than the one in controls 57 (OR=2.21; 95% CI: 1.13-4.31; P=0.01). Men with insomnia had a higher (8/73: 11.0%) rate 58 of high anti-T. gondii IgG antibody levels than men without insomnia (0/73: 0.0%) 59 (P=0.006). The rate of high anti-T. gondii IgG antibody levels in cases >50 years old (11/180: 60 6.1%) was higher than that (3/180: 1.7%) in controls of the same age group (OR: 3.84; 95%) 61 CI: 1.05-14.00; P=0.05). No difference in the rate of IgM seropositivity between cases and 62 controls was found (OR=1.33; 95% CI: 0.57-3.11; P=0.50).

63 Conclusions: Results of this seroepidemiology study suggest that infection with *T. gondii* is 64 associated with insomnia. Men older than 50 years with *T. gondii* exposure might be prone 65 to insomnia. Further research to confirm the association between seropositivity and 66 serointensity to *T. gondii* and insomnia are needed.

67

68

# 70 Keywords:

*Toxoplasma gondii*; insomnia; case-control study; seroprevalence; epidemiology.

## 75 Introduction

76 Toxoplasma gondii (T. gondii) is an obligate intracellular parasite [1]. Toxoplasmosis, 77 the disease caused by T. gondii, is a zoonosis with medical and veterinary importance 78 worldwide [2]. T. gondii infects one third of the global human population [3]. Foodborne 79 transmission of T. gondii in humans occurs mainly by eating undercooked meat, especially 80 pork, lamb, and wild game meat from T. gondii-infected animals, and ingestion of raw fruits 81 and vegetables contaminated with soil containing cat feces [4]. Transmission of T. gondii 82 may also occur by blood transfusion, tissue transplants, or ingestion of unpasteurized milk 83 [5]. In addition, T. gondii can be transmitted vertically during pregnancy [6]. Infections with 84 T. gondii may result in a clinical spectrum ranging from a completely asymptomatic infection 85 to multi-organ involvement [7]. Some patients with toxoplasmosis present cervical 86 lymphadenopathy or ocular disease, whereas a reactivation of latent disease in 87 immunocompromised patients can cause life-threatening encephalitis [8]. Chronic 88 toxoplasmosis might be responsible for a vast array of neuropsychiatric symptoms [9]. 89 Seroprevalence of T. gondii infection has been linked to mixed anxiety and depressive 90 disorder [10], schizophrenia [11, 12], depression [13, 14], and suicide behavior [14-15]. Few 91 studies have shown a link between T. gondii infection and insomnia. However, results of 92 such studies are controversial. In a study of students, a positive association between 93 seropositivity to T. gondii and insomnia was found in women but not in men [16]. In two 94 further studies, researchers found that T. gondii IgG seropositivity and serointensity were not 95 associated with insomnia [17, 18]. T. gondii can disseminate to brain in infected hosts [19], 96 and we hypothesize that T. gondii can involve brain structures related with sleep leading to 97 sleep problems as insomnia. Several neurotransmitters are involved in sleep including for

- 98 instance, dopamine and gamma-aminobutyric acid (GABA) [20], and T. gondii infections
- 99 impact on these two neurotransmitters. *T. gondii* infections alter the dopamine metabolism
- 100 [21], and GABAergic synapses and signaling in the central nervous system [22]. Therefore,
- 101 this study was aimed to determine the association between *T. gondii* exposure and insomnia
- 102 in a sample of people in Durango, Mexico.

## 104 Methods

## 105 Study design and study population

106 Through a cross-sectional, age- and gender-matched case-control study, 577 people 107 with insomnia (cases) and 577 people without insomnia (controls) were examined for the 108 presence of *T. gondii* exposure. This study was performed in the northern Mexican state of 109 Durango from 2014 to 2019. Cases and controls were individuals attending public health care 110 institutions for medical consultations or laboratory tests. Inclusion criteria for cases were 111 people with insomnia, aged  $\geq 18$  years, with informed consent. Gender, occupation, and 112 socioeconomic status were not restrictive criteria for enrollment of cases or controls. The 113 Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) defines 114 insomnia as a predominant complain of dissatisfaction with sleep quantity or quality, 115 associated with one (or more) of the following symptoms: difficulty initiating sleep, 116 difficulty maintaining sleep, and early-morning awakening with inability to return to sleep 117 [23]. Inclusion criteria for enrollment of controls were people without insomnia, aged  $\geq 18$ 118 years, with informed consent. Of the 577 cases, 505 (87.5%) were women and 72 (12.5%) 119 were men. They were 18-80 years old (mean:  $43.63 \pm 12.55$ ). Whereas of the 577 controls, 120 503 (87.2%) were women and 74 (12.8%) were men. They were 18-81 years old (mean: 121  $43.63 \pm 12.56$ ). There were no differences in age (P=0.99) or gender (P=0.93) among cases 122 and controls.

123

#### 124 Laboratory tests

Five ml of venous blood was drawn from each participant. After blood clotting, blood
samples were centrifuged. Serum was transferred into microtubes and kept at -20° C until

127 assayed. All samples were analyzed for anti-T. gondii IgG antibodies using the commercially available enzyme-linked immunoassay "Toxoplasma gondii IgG" kit (Diagnostic 128 129 Automation/Cortez Diagnostics, Inc., Woodland Hills, California. USA). This test allows 130 detection and quantification of anti-T. gondii IgG antibodies. A cut-off of 8 IU/ml was used 131 to determine seropositivity. Serum samples with anti-T. gondii IgG antibodies were further 132 analyzed for detection of anti-T. gondii IgM antibodies by the commercially available enzyme-linked immunoassay "Toxoplasma gondii IgM" kit (Diagnostic Automation/Cortez 133 134 Diagnostics, Inc.). Positive and negative controls were included in each run. All 135 immunoassays were carried out as described in the manufacturer's instructions.

136

#### 137 Statistical analysis

138 Data analysis was performed using the software SPSS Statistics version 15. A sample 139 size of 577 cases and 577 controls was calculated using the following parameters: a reference 140 seroprevalence of 6.1% [24] as the expected frequency of exposure in controls, a two-sided 141 confidence level of 95%, a power of 90%, a 1:1 proportion of cases and controls, and an odds 142 ratio of 2.0. The student's t-test was used to assess age matching. To compare the frequencies 143 among the groups the Pearson's chi-square test or the Fisher's exact test (when a value was 144 below 5) were used. Odd ratios (OR) and corresponding 95% confidence intervals (CI) were 145 calculated. A statistical P value of  $\leq 0.05$  was considered significant for all comparisons.

146

### 147 **Ethical aspects**

148 The Ethical Committees of the Institute of Security and Social Services for the State 149 Workers and the General Hospital of the Secretary of Health in Durango City, Mexico 150 approved this project. A written informed consent from each participant was obtained.

153 **Results** 

154 Anti-T. gondii IgG antibodies were found in 71 (12.3%) of 577 individuals with 155 insomnia and in 46 (8.0%) of 577 controls. A statistically significant difference (OR=1.62; 156 95% CI: 1.09-2.39; P=0.01) in anti-T. gondii IgG seroprevalence between cases and controls 157 was found. A stratification by age and sex and seroprevalence of T. gondii infection in 158 individuals with and without insomnia is shown in Table 1. Stratification by sex showed that 159 men with insomnia had a significantly higher (16/73: 21.9%) seroprevalence of T. gondii 160 infection than men without insomnia (5/73: 6.8%) (OR: 3.81; 95% CI: 1.31-11.06; P=0.009). 161 Whereas stratification by age groups showed that seroprevalence of T. gondii infection in 162 cases was similar to controls regardless their age groups. Of the 71 anti-T. gondii IgG positive 163 cases, 28 (39.4%) had anti-T. gondii IgG antibody levels higher than 150 IU/ml, 6 (8.5%) 164 between 100 IU/ml and 150 IU/ml, and 37 (52.1%) between 8 to 99 IU/ml. On the other 165 hand, of the 46 anti-T. gondii IgG positive controls, 13 (28.2%) had anti-T. gondii IgG 166 antibody levels higher than 150 IU/ml, 5 (10.9%) between 100 IU/ml and 150 IU/ml, and 28 (60.9%) between 8 to 99 IU/ml. A statistically significant difference (OR=2.21; 95% CI: 167 168 1.13-4.31; P=0.01) in the frequency of individuals with high (>150 IU/ml) anti-T. gondii IgG 169 antibody levels between cases and controls was found. A stratification by sex and age groups 170 and the rates of high (>150 IU/ml) anti-T. gondii IgG antibody levels in cases and controls is 171 shown in Table 2. Stratification by sex showed that men with insomnia had a significantly 172 higher (8/73: 11.0%) rate of high anti-T. gondii IgG antibody levels than men without 173 insomnia (0/73: 0.0%) (P=0.006). Whereas stratification by age groups showed that the rate 174 of high anti-T. gondii IgG antibody levels in cases >50 years old (11/180: 6.1%) was higher 175 than that (3/180: 1.7%) in controls of the same age group (OR: 3.84; 95% CI: 1.05-14.00;

176	P=0.05). Of the 71 anti-T. gondii IgG antibody seropositive cases, 21 (29.6%) were also
177	positive for anti-T. gondii IgM antibodies. Whereas, of the 46 anti-T. gondii IgG antibody
178	seropositive controls, 11 (23.9%) were also positive for anti-T. gondii IgM antibodies. No
179	difference in the rate of IgM seropositivity between cases and controls was found (OR=1.33;
180	95% CI: 0.57-3.11; <i>P</i> =0.50).
181	
182	
183	
184	
185	
186	
187	
188	
189	

## 192 **Discussion**

193 There are only few studies that have assessed the epidemiological link between T. 194 gondii infection and insomnia. Results of such studies are controversial and there is currently 195 scanty information as to state whether T. gondii exposure leads to insomnia. Therefore, in 196 this age- and gender-matched case-control study we attempted to determine the association 197 between *T. gondii* exposure and insomnia in a sample of people in the northern Mexican state 198 of Durango. We observed a significantly higher seroprevalence of T. gondii infection in 199 individuals with insomnia than in individuals without insomnia. In addition, we found a 200 significantly higher rate of high anti-T. gondii IgG antibody levels in cases than in controls. 201 Therefore, our results suggest that T. gondii seropositivity and serointensity are positively 202 associated with insomnia. However, the association of T. gondii seropositivity and insomnia 203 was observed in men but not in women, and the association between *T. gondii* serointensity 204 and insomnia was found only in men and in individuals aged >50 years. The positive 205 association between T. gondii seropositivity and insomnia found in our study contrast with 206 that found in a previous study of 200 students in Iran, where investigators observed a positive 207 association between T. gondii seroprevalence and insomnia in women but not in men [16]. It 208 is not clear why the association between seropositivity and insomnia was found only in men 209 in our study. It is unknown whether men are more vulnerable than women to the clinical 210 effects of T. gondii. It is possible that factors associated with T. gondii exposure in men were 211 different from those in women in our study. Further research to determine the association 212 between sociodemographic, clinical, and behavioral factors and T. gondii exposure in men 213 with insomnia is needed. On the other hand, results of our study also contrast with the 214 findings of two more studies. In a study of 311 older adults recruited in a psychiatric institute

215 and clinic in Pittsburg, USA, researchers found no association between insomnia and T. 216 gondii seroprevalence and serointensity [17]. In a study of 2031 Old Order Amish individuals 217 recruited in Lancaster County, USA, researchers found no association between T. gondii 218 seropositivity and serointensity and insomnia [18]. Difference in the association between T. 219 gondii exposure and insomnia among the studies might be due to differences in the 220 characteristics of the study populations. We studied people enrolled at several health care 221 institutions whereas researchers of other studies enrolled students [16], older adults [17], and 222 Old Order Amish individuals [18]. In addition, there are differences in the sample size and 223 study design among the studies. We used an age- and gender-matched case-control study 224 design and studied 577 cases and 577 controls whereas in another study 180 people suffering 225 from insomnia and 131 normal sleeping participants with no differences in age, gender and 226 race were studied [17]. The study of students was cross-sectional and had 200 participants 227 [16]; and the study of Old Order Amish was cross-sectional and included 2031 participants 228 [18]. Risk factors for *T. gondii* exposure and host factors might be different among the study 229 populations. In addition, differences in the virulence of T. gondii strains among infected hosts 230 might exist. Further research to determine the association between insomnia and T. gondii 231 seropositivity and serointensity are needed.

232

#### 233 **Conclusions:**

Results of this age- and gender-matched case-control study suggest that infection with *T. gondii* is associated with insomnia. Men older than 50 years with *T. gondii* exposure might be prone to insomnia. Further research to confirm the association between seropositivity and serointensity to *T. gondii* and insomnia are needed.

238	
239	Conflict of interest:
240	The authors declare that no conflict of interest exists.
241	
242	Funding:
243	This study was financially supported by Secretary of Public Education, Mexico
244	(Grant No. DSA/103.5/14/11311).
245	
246	

249	Referen	ces
-----	---------	-----

250	1. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for
251	toxoplasmosis. Clin Microbiol Rev. 2012 Apr;25(2):264-96. doi: 10.1128/CMR.05013-11.
252	
253	2. Liu Q, Wang ZD, Huang SY, Zhu XQ. Diagnosis of toxoplasmosis and typing of
254	Toxoplasma gondii. Parasit Vectors. 2015 May 28;8:292. doi: 10.1186/s13071-015-0902-6.
255	
256	3. Schlüter D, Barragan A. Advances and Challenges in Understanding Cerebral
257	Toxoplasmosis. Front Immunol. 2019 Feb 14;10:242. doi: 10.3389/fimmu.2019.00242.
258	
259	4. Jones JL, Dubey JP. Foodborne toxoplasmosis. Clin Infect Dis. 2012 Sep;55(6):845-51.
260	doi: 10.1093/cid/cis508.
261	
262	5. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int
263	J Parasitol. 2000 Nov;30(12-13):1217-58. doi: 10.1016/s0020-7519(00)00124-7.
264	
265	6. Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human
266	toxoplasmosis: a systematic review. Pathog Glob Health. 2017 Oct;111(7):333-342. doi:
267	10.1080/20477724.2017.1370528.
268	
269	7. Fabiani S, Pinto B, Bruschi F. Toxoplasmosis and neuropsychiatric diseases: can
270	serological studies establish a clear relationship? Neurol Sci. 2013 Apr;34(4):417-25. doi:
271	10.1007/s10072-012-1197-4.

8. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004 Jun 12;363(9425):1965-76. doi:
10.1016/S0140-6736(04)16412-X.

275

9. Fuglewicz AJ, Piotrowski P, Stodolak A. Relationship between toxoplasmosis and
schizophrenia: A review. Adv Clin Exp Med. 2017 Sep;26(6):1031-1036. doi:
10.17219/acem/61435.

279

- 280 10. Alvarado-Esquivel C, Sanchez-Anguiano LF, Hernandez-Tinoco J, Berumen-Segovia
- 281 LO, Torres-Prieto YE, Estrada-Martinez S, Perez-Alamos AR, Ortiz-Jurado MN, Molotla-

de-Leon G, Beristain Garcia I, Rabago-Sanchez E, Liesenfeld O. Toxoplasma gondii infection and mixed anxiety and depressive disorder: a case-control seroprevalence study in

- 284 Durango, Mexico. J Clin Med Res. 2016 Jul;8(7):519-23. doi: 10.14740/jocmr2576w.
- 285
- 11. Stepanova EV, Kondrashin AV, Sergiev VP, Morozova LF, Turbabina NA, Maksimova
  MS, Romanov DV, Kinkulkina MA, Lazareva AV, Morozov EN. Toxoplasmosis and mental
  disorders in the Russian Federation (with special reference to schizophrenia). PLoS One.
  2019 Jul 10;14(7):e0219454. doi: 10.1371/journal.pone.0219454.
- 290
- 12. Alvarado-Esquivel C, Urbina-Álvarez JD, Estrada-Martínez S, Torres-Castorena A,
  Molotla-de-León G, Liesenfeld O, Dubey JP. Toxoplasma gondii infection and
  schizophrenia: a case control study in a low Toxoplasma seroprevalence Mexican population.
  Parasitol Int. 2011 Jun;60(2):151-5. doi: 10.1016/j.parint.2010.12.003.
- 295

13. Alvarado-Esquivel C, Sánchez-Anguiano LF, Hernández-Tinoco J, Berumen-Segovia
LO, Torres-Prieto YE, Estrada-Martínez S, Pérez-Álamos AR, Ortiz-Jurado MN, Molotlade-León G, Beristain-García I, Rábago-Sánchez E, Liesenfeld O. Toxoplasma gondii
infection and depression: a case-control seroprevalence study. Eur J Microbiol Immunol
(Bp). 2016 Apr 25;6(2):85-9. doi: 10.1556/1886.2016.00010.

301

14. Kamal AM, Kamal AM, Abd El-Fatah AS, Rizk MM, Hassan EE. Latent toxoplasmosis
is associated with depression and suicidal behavior. Arch Suicide Res. 2020 Nov 9:1-12. doi:
10.1080/13811118.2020.1838368.

305

15. Alvarado-Esquivel C, Estrada-Martínez S, Ramos-Nevárez A, Pérez-Álamos AR,
Beristain-García I, Alvarado-Félix ÁO, Cerrillo-Soto SM, Sifuentes-Álvarez A, AlvaradoFélix GA, Guido-Arreola CA, Saenz-Soto L. Association between Toxoplasma gondii
exposure and suicidal behavior in patients attending primary health aare clinics. Pathogens.
2021 May 30;10(6):677. doi: 10.3390/pathogens10060677.

311

16. Khademvatan S, Izadi-Mazidi M, Saki J, Khajeddin N. Mental health and latent
toxoplasmosis: comparison of individuals with and without anti-Toxoplasma antibodies.
World Health Popul. 2016;17(1):39-46. doi: 10.12927/whp.2016.24938.

315

316 17. Meshreky KM, Wood J, Chowdari KV, Hall MH, Wilckens KA, Yolken R, Buysse DJ, 317 Nimgaonkar VL. Infection with Herpes Simplex virus type 1 (HSV-1) and sleep: The dog 318 did that bark. Psychiatry Res. 2019 Oct;280:112502. doi: not 319 10.1016/j.psychres.2019.112502.

321	18. Ahmad Z, Moustafa YW, Stiller JW, Pavlovich MA, Raheja UK, Gragnoli C, Snitker S,
322	Nazem S, Dagdag A, Fang B, Fuchs D, Lowry CA, Postolache TT. Sleep onset insomnia,
323	daytime sleepiness and sleep duration in relationship to Toxoplasma gondii IgG
324	seropositivity and serointensity. Pteridines. 2017;28(3-4):195-204. doi: 10.1515/pterid-
325	2017-0010.
326	
327	19. Schlüter D, Barragan A. Advances and Challenges in Understanding Cerebral
328	Toxoplasmosis. Front Immunol. 2019 Feb 14;10:242. doi: 10.3389/fimmu.2019.00242.
329	
330	20. Murillo-Rodriguez E, Arias-Carrion O, Zavala-Garcia A, Sarro-Ramirez A, Huitron-
331	Resendiz S, Arankowsky-Sandoval G. Basic sleep mechanisms: an integrative review. Cent
332	Nerv Syst Agents Med Chem. 2012 Mar;12(1):38-54. doi: 10.2174/187152412800229107.
333	
334	21. Parlog A, Schlüter D, Dunay IR. Toxoplasma gondii-induced neuronal alterations.
335	Parasite Immunol. 2015 Mar;37(3):159-70. doi: 10.1111/pim.12157.
336	
337	22. Brooks JM, Carrillo GL, Su J, Lindsay DS, Fox MA, Blader IJ. Toxoplasma gondii
338	infections alter GABAergic synapses and signaling in the central nervous system. mBio.
339	2015 Oct 27;6(6):e01428-15. doi: 10.1128/mBio.01428-15.
340	
341	23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
342	Disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
343	

344	24. Alvarado-Esquivel C, Estrada-Martínez S, Pizarro-Villalobos H, Arce-Quiñones M,
345	Liesenfeld O, Dubey JP. Seroepidemiology of Toxoplasma gondii infection in general
346	population in a northern Mexican city. J Parasitol. 2011 Feb;97(1):40-3. doi: 10.1645/GE-
347	2612.1.
348	
349	
350	
351	
352	
353	
354	
355	
356	
357	
358	
359	
360	
361	
362	

No. ested	Seropo to T. 2 No.	ositivity g <i>ondii</i> %	No.	Seropo to <i>T.</i> g	sitivity zondii	Odds	95% confidence	D
No. ested	to <i>T.</i> 2 No.	gondii %	No.	to T. g	gondii	Odds	confidence	D
ested	No.	%	tastad		,	0.440	connucliee	1
			iesieu	No.	%	ratio	interval	value
73	16	21.9	73	5	6.8	3.81	1.31 - 11.06	0.009
504	55	10.9	504	41	8.1	1.38	0.90 - 2.11	0.13
99	9	9.1	99	5	5.1	1.80	0.60 - 5.82	0.26
298	37	12.4	298	27	9.1	1.42	0.84 - 2.40	0.18
180	25	13.9	180	14	7.8	1.91	0.96 - 3.81	0.06
577	71	12.3	577	46	8.0	1.62	1.09 - 2.39	0.01
1	73 504 99 298 80 577	73       16         504       55         99       9         98       37         80       25         577       71	73       16       21.9         504       55       10.9         99       9       9.1         298       37       12.4         80       25       13.9         577       71       12.3	73       16       21.9       73         504       55       10.9       504         99       9       9.1       99         98       37       12.4       298         80       25       13.9       180         577       71       12.3       577	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	7316 $21.9$ $73$ 5 $6.8$ $3.81$ $504$ $55$ $10.9$ $504$ $41$ $8.1$ $1.38$ $99$ 99.1995 $5.1$ $1.80$ $998$ $37$ $12.4$ $298$ $27$ $9.1$ $1.42$ $80$ $25$ $13.9$ $180$ $14$ $7.8$ $1.91$ $577$ $71$ $12.3$ $577$ $46$ $8.0$ $1.62$	73       16       21.9       73       5       6.8       3.81       1.31 - 11.06         504       55       10.9       504       41       8.1       1.38       0.90 - 2.11         99       9       9.1       99       5       5.1       1.80       0.60 - 5.82         98       37       12.4       298       27       9.1       1.42       0.84 - 2.40         80       25       13.9       180       14       7.8       1.91       0.96 - 3.81         577       71       12.3       577       46       8.0       1.62       1.09 - 2.39

Table 1. Stratification by sex and age in cases and controls and seropositivity rates to *T. gondii*.

Table 2.	Stratification	by sex and	age in c	cases and	controls	and rates o	of high (≥	150
IU/ml)								

	(	Cases		Co	ntrols				
		≥1	50		≥1	50			
		IU	/ml		IU	/ml			
		ant	ti- <i>T</i> .		ant	i- <i>T</i> .			
		go	ndii		<i>gor</i> Ig	ndii G			
	No.	IgG	levels	No.	lev	els	Odds	confidence	Р
Characteristics	tested	No.	%	tested	No.	%	ratio	interval	value
Sex									
Male	73	8	11.0	73	0	0.0			0.006
Female	504	20	4.0	504	13	2.6	1.56	0.76-3.17	0.21
Age (years)									
≤30	99	4	4.0	99	1	1.0	4.12	0.45-37.60	0.36
31-50	298	13	4.4	298	9	3.0	1.46	0.61-3.48	0.38
>50	180	11	6.1	180	3	1.7	3.84	1.05-14.00	0.05
A11	577	28	4.9	577	13	2.3	2.21	1.13-4.31	0.01

## anti-T. gondii IgG antibody levels.